| Literature DB >> 33087340 |
Yifei Zhang1, Juan Shi1, Ying Peng1, Zhiyun Zhao1, Qidong Zheng2, Zilong Wang3, Kun Liu4, Shengyin Jiao3, Kexin Qiu3, Ziheng Zhou3,5, Li Yan6, Dong Zhao7, Hongwei Jiang8, Yuancheng Dai9, Benli Su10, Pei Gu11, Heng Su12, Qin Wan13, Yongde Peng14, Jianjun Liu15, Ling Hu16, Tingyu Ke17, Lei Chen18, Fengmei Xu19, Qijuan Dong20, Demetri Terzopoulos21,22, Guang Ning1, Xun Xu4, Xiaowei Ding23,5, Weiqing Wang24.
Abstract
INTRODUCTION: Early screening for diabetic retinopathy (DR) with an efficient and scalable method is highly needed to reduce blindness, due to the growing epidemic of diabetes. The aim of the study was to validate an artificial intelligence-enabled DR screening and to investigate the prevalence of DR in adult patients with diabetes in China. RESEARCH DESIGN AND METHODS: The study was prospectively conducted at 155 diabetes centers in China. A non-mydriatic, macula-centered fundus photograph per eye was collected and graded through a deep learning (DL)-based, five-stage DR classification. Images from a randomly selected one-third of participants were used for the DL algorithm validation.Entities:
Keywords: clinical study; diabetic retinopathy; diagnostic techniques and procedures; epidemiology
Mesh:
Year: 2020 PMID: 33087340 PMCID: PMC7580048 DOI: 10.1136/bmjdrc-2020-001596
Source DB: PubMed Journal: BMJ Open Diabetes Res Care ISSN: 2052-4897
Figure 1Fundus image grading work flow and adjudication. DL, deep learning; DR, diabetic retinopathy.
Clinical characteristics of the study participants
| Total | By sex stratification | P value | ||
| Male | Female | |||
| Age, years | 54.29±11.60 | 52.76±11.58 | 56.35±11.29 | <0.001 |
| High school education and above | 17 661 (43.0) | 12 301 (51.5) | 5360 (31.2) | <0.001 |
| Han Chinese ethnicity | 37 457 (96.1) | 21 788 (95.9) | 15 669 (96.4) | 0.010 |
| Family history of diabetes | 16 294 (40.1) | 9271 (39.3) | 7023 (41.3) | <0.001 |
| Duration of diabetes, years | 6.80±6.71 | 6.31±6.50 | 7.47±6.93 | <0.001 |
| History of hypertension | 16 266 (39.8) | 8835 (37.2) | 7431 (43.4) | <0.001 |
| History of dyslipidemia | 11 361 (27.9) | 6825 (28.8) | 4536 (26.5) | <0.001 |
| Body mass index, kg/m2 | 25.62±3.77 | 25.77±3.63 | 25.42±3.95 | <0.001 |
| Waist circumference, cm | 91.07±10.29 | 92.73±9.83 | 88.80±10.49 | <0.001 |
| Systolic blood pressure, mm Hg | 131.40±19.06 | 130.36±18.23 | 132.81±20.04 | <0.001 |
| Diastolic blood pressure, mm Hg | 77.34±11.34 | 78.70±11.28 | 75.51±11.16 | <0.001 |
| HbA1c, % | 9.06±2.27 | 9.14±2.32 | 8.94±2.20 | <0.001 |
| HbA1c, mmol/mol | 75.45±24.85 | 76.36±25.34 | 74.18±24.09 | <0.001 |
| Fasting blood glucose, mmol/L | 9.34±3.74 | 9.38±3.80 | 9.27±3.66 | 0.005 |
| Postprandial blood glucose, mmol/L | 16.16±5.44 | 16.10±5.33 | 16.24±5.58 | 0.016 |
| Triglyceride, mmol/L | 2.27±2.35 | 2.39±2.59 | 2.09±1.96 | <0.001 |
| Total cholesterol, mmol/L | 4.83±1.36 | 4.73±1.36 | 4.98±1.33 | <0.001 |
| LDL cholesterol, mmol/L | 2.79±1.00 | 2.74±0.97 | 2.87±1.03 | <0.001 |
| Serum creatine, μmol/L | 66.67±30.43 | 73.69±31.45 | 56.88±25.96 | <0.001 |
| Urinary acid, μmol/L | 317.83±96.50 | 338.38±96.70 | 289.15±88.57 | <0.001 |
Data are given as a mean±SD or as a number and percentage in parentheses. Comparisons of mean values and proportions by sex were performed using the Student’s t-test and χ2 tests, respectively.
HbA1c, glycated hemoglobin; LDL, low-density lipoprotein.
Figure 2Geographic distribution of the 155 metabolic management centers in China involved in this study.
Prevalence of diabetic retinopathy (DR), referable DR and vision-threatening DR (VTDR) in total and among different risk factor stratification
| Prevalence % (95% CI) | No. of patients | |||
| DR | Referable DR | VTDR | ||
| Total | 28.8 (28.4 to 29.3) | 24.4 (24.0 to 24.8) | 10.8 (10.5 to 11.1) | 40 665 |
| Gender | ||||
| Male | 28.3 (27.7 to 28.8) | 23.5 (23.0 to 24.1) | 10.0 (9.6 to 10.4) | 23 686 |
| Female | 29.6 (28.9 to 30.3) | 25.5 (24.9 to 26.2) | 11.9 (11.4 to 12.4) | 16 979 |
| Age groups, years | ||||
| 18–29 | 18.7 (16.6 to 20.8) | 12.7 (10.9 to 14.4) | 6.2 (4.9 to 7.5) | 1375 |
| 30–39 | 22.9 (21.6 to 24.3) | 17.0 (15.8 to 18.2) | 6.8 (6.0 to 7.6) | 3775 |
| 40–49 | 27.9 (26.9 to 29.0) | 22.2 (21.4 to 23.1) | 8.9 (8.3 to 9.5) | 8650 |
| 50–59 | 30.2 (29.5 to 31.0) | 25.6 (24.8 to 26.3) | 11.0 (10.5 to 11.5) | 14 231 |
| 60–69 | 30.2 (29.3 to 31.1) | 27.1 (26.3 to 28.0) | 12.5 (11.9 to 13.2) | 10 304 |
| ≥70 | 33.5 (31.6 to 35.4) | 31.8 (29.9 to 33.7) | 18.0 (16.5 to 19.6) | 2330 |
| Diabetic duration, years | ||||
| <5 | 20.0 (19.4 to 20.6) | 15.6 (15.0 to 16.1) | 5.9 (5.5 to 6.2) | 17 175 |
| 5–10 | 30.8 (29.9 to 31.8) | 25.7 (24.7 to 26.7) | 10.7 (10.0 to 11.4) | 7246 |
| 10–15 | 41.4 (40.1 to 42.7) | 35.9 (34.6 to 37.1) | 16.8 (15.8 to 17.8) | 5403 |
| 15–20 | 49.1 (47.1 to 51.1) | 44.3 (42.3 to 46.2) | 22.1 (20.4 to 23.7) | 2426 |
| ≥20 | 52.5 (50.0 to 54.9) | 48.0 (45.5 to 50.4) | 10.7 (9.9 to 11.4) | 1618 |
| HbA1c, % | ||||
| <6.5 | 18.4 (17.1 to 19.6) | 14.9 (13.7 to 16.0) | 6.4 (5.6 to 7.1) | 3778 |
| 6.5–6.9 | 21.2 (19.8 to 22.7) | 17.2 (15.8 to 18.5) | 7.3 (6.4 to 8.2) | 3046 |
| 7.0–7.9 | 26.5 (25.4 to 27.6) | 21.7 (20.7 to 22.8) | 9.5 (8.7 to 10.2) | 6208 |
| 8.0–8.9 | 32.9 (31.7 to 34.2) | 27.3 (26.1 to 28.4) | 11.2 (10.4 to 12.0) | 5685 |
| 9.0–9.9 | 34.0 (32.6 to 35.3) | 29.4 (28.2 to 30.7) | 12.4 (11.5 to 13.3) | 4941 |
| ≥10.0 | 33.3 (32.5 to 34.2) | 28.4 (27.6 to 29.2) | 13.0 (12.4 to 13.6) | 11 338 |
CSME, clinically significant macular edema; DR, diabetic retinopathy; HbA1c, glycated hemoglobin; VTDR, vision-threatening diabetic retinopathy.